vps-33.2 Antibody

What is VPS-33.2 and how does it differ from VPS-33.1?

VPS-33.2 (also known as VPS33B in mammals) is one of two Vps33 homologs found in metazoan cells. While yeast has only one Vps33 protein, metazoans possess both VPS-33.1 (VPS33A) and VPS-33.2 (VPS33B) with distinct biological roles. VPS-33.2 belongs to the STXBP/unc-18/SEC1 family and functions in vesicle-mediated protein trafficking to lysosomal compartments and membrane docking/fusion reactions in late endosomes/lysosomes .

The key functional differences between these proteins are:

• VPS-33.1 shares most general functions with yeast Vps33 in tethering complexes of the endolysosomal system

• VPS-33.2 has tissue/organelle-specific functions, particularly in reproductive tissues

• Expression of VPS-33.2 cannot rescue endocytosis defects in VPS-33.1 mutants, indicating non-redundant functions

• VPS-33.2 forms part of the CHEVI complex with SPE-39/VIPAS39, while VPS-33.1 is associated with the HOPS complex

What model organisms are suitable for VPS-33.2 research?

Based on current research, several model systems have proven valuable for studying VPS-33.2:

When selecting a model system, consider the specific biological question and available genetic tools for manipulating VPS-33.2 expression.

What are the standard applications for VPS-33.2 antibodies?

VPS-33.2/VPS33B antibodies can be employed in multiple experimental techniques:

For optimal results, polyclonal antibodies targeting VPS33B require antigen affinity purification and should be stored at -20°C in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3) .

How should I design experiments to investigate VPS-33.2 function in vesicular trafficking?

When investigating VPS-33.2 function in vesicular trafficking, consider these methodological approaches:

• Loss-of-function studies: Generate null mutants or knockdowns of VPS-33.2. In C. elegans, VPS-33.2 null mutants remain viable but exhibit sterility due to terminally arrested spermatocytes, suggesting roles in sperm-specific organelle formation .

• Rescue experiments: Test tissue specificity by expressing VPS-33.2 in VPS-33.1 mutant backgrounds. Research shows VPS-33.2 cannot compensate for VPS-33.1 deficiency in endocytosis, demonstrating their non-redundant functions .

• Protein complex analysis: Investigate VPS-33.2 interactions with binding partners using techniques like co-immunoprecipitation. VPS-33.2 directly binds to SPE-39 as part of the CHEVI complex, while VPS-33.1 does not interact with SPE-39 .

• Subcellular localization: Use immunofluorescence microscopy with organelle markers to determine VPS-33.2 localization patterns in different cell types and compare with VPS-33.1 distribution.

• Cargo trafficking assays: Monitor trafficking of specific cargoes in wildtype versus VPS-33.2-deficient cells to identify specific trafficking routes dependent on VPS-33.2 function.

What controls should be included when working with VPS-33.2 antibodies?

Robust experimental design requires appropriate controls:

• Positive controls: Include tissues/cells known to express VPS33B, such as HEK-293, HeLa, mouse skeletal muscle, or testis samples .

• Negative controls:

  • Primary antibody omission

  • Isotype controls (rabbit IgG)

  • Tissues from VPS-33.2/VPS33B knockout models

  • Blocking peptide competition assays

• Specificity validation: Test antibody specificity through:

  • Western blot showing expected 65-71 kDa band

  • Knockdown/knockout validation showing signal reduction

  • Comparing multiple antibodies targeting different epitopes

• Cross-reactivity assessment: When studying VPS-33.2, evaluate potential cross-reactivity with the structurally similar VPS-33.1/VPS33A protein.

How can I resolve discrepancies between VPS-33.2 antibody results and genetic data?

Researchers may encounter inconsistencies between antibody-based detection and genetic analyses of VPS-33.2. To address these:

• Validate antibody specificity: Confirm antibody specificity using VPS-33.2 knockout/knockdown samples. The calculated molecular weight of VPS33B is 71 kDa, but it may be observed at 65-71 kDa range on Western blots .

• Consider expression levels: VPS-33.2 may have tissue-specific expression patterns. In C. elegans, VPS-33.2 shows specific functions in spermatogenesis .

• Evaluate post-translational modifications: Investigate whether discrepancies result from protein modifications affecting antibody recognition or protein mobility.

• Examine genetic compensation: In genetic models, compensatory mechanisms may mask phenotypes. Compare acute depletion (RNAi/CRISPR) with chronic loss (stable mutants).

• Cross-species considerations: When applying findings across species, remember that while the VPS-33.2 function in CHEVI complex formation appears conserved, specific roles may vary between organisms .

What methodological approaches are recommended for studying VPS-33.2 interactions?

To investigate VPS-33.2 protein interactions:

• Co-immunoprecipitation: Use anti-VPS33B antibodies to pull down protein complexes. This approach revealed that VPS-33.2/VPS33B interacts with SPE-39/VIPAS39 in the CHEVI complex .

• Yeast two-hybrid assays: This method successfully demonstrated direct binding between SPE-39 and VPS-33.2 in C. elegans studies .

• Bacterial co-expression: Express tagged versions of VPS-33.2 and potential interactors in E. coli to test direct binding. GST-tagged SPE-39 co-purified with His-tagged VPS-33.2 but not with VPS-33.1, confirming specific interaction .

• Proximity labeling: Techniques like BioID or APEX2 can identify proteins in close proximity to VPS-33.2 in living cells.

• Fluorescence resonance energy transfer (FRET): To study dynamic interactions in live cells, tag VPS-33.2 and potential partners with compatible fluorophores.

How does VPS-33.2 dysfunction relate to human pathologies?

VPS33B defects have significant clinical implications:

• Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: Defects in VPS33B account for most cases of this multisystem disorder characterized by abnormalities in polarized liver and kidney cells .

• Experimental approaches to study disease mechanisms:

  • Patient-derived cells to examine trafficking defects

  • Rescue experiments with wildtype VPS33B in patient cells

  • Animal models recapitulating ARC syndrome features

  • Tissue-specific knockout models to identify organ-specific effects

• Biomarker potential: Consider whether VPS33B antibody staining patterns could serve as diagnostic tools for disorders related to vesicular trafficking defects.

What are the optimal conditions for VPS-33.2 antibody storage and use?

For maximum stability and performance of VPS33B antibodies:

How should I troubleshoot weak or non-specific VPS-33.2 antibody signals?

When encountering issues with VPS-33.2 antibody performance:

• Weak signal troubleshooting:

  • Increase antibody concentration

  • Extend incubation time

  • Enhance detection system sensitivity

  • Enrich target protein through immunoprecipitation

  • Confirm VPS-33.2 expression in the tissue/cells being tested

• Non-specific binding remediation:

  • Increase blocking reagent concentration

  • Extend blocking time

  • Try alternative blocking agents (BSA, normal serum, casein)

  • Perform additional washing steps

  • Reduce primary antibody concentration

  • Pre-adsorb antibody with non-specific proteins

• Sample preparation optimization:

  • Ensure proper fixation for immunohistochemistry/immunofluorescence

  • Use fresh samples when possible

  • Include protease inhibitors during protein extraction

• Controls to identify issues:

  • Secondary antibody-only controls to assess background

  • Positive control samples with known VPS-33.2 expression

  • Test multiple antibodies targeting different epitopes

What emerging technologies might advance VPS-33.2 research?

Several cutting-edge approaches show promise for deepening our understanding of VPS-33.2:

• Super-resolution microscopy: Techniques like STED, PALM, or STORM can provide nanoscale resolution of VPS-33.2 localization relative to vesicular compartments.

• CRISPR-based approaches:

  • CRISPRi for temporal control of VPS-33.2 expression

  • CRISPR activation to upregulate VPS-33.2 in specific contexts

  • CRISPR screens to identify genetic interactions with VPS-33.2

• Protein structure determination: Cryo-EM or X-ray crystallography of VPS-33.2 alone or in complex with interaction partners could reveal structural mechanisms.

• Organoid models: Study VPS-33.2 function in more physiologically relevant 3D tissue models, particularly for polarized epithelia relevant to ARC syndrome.

• Single-cell analyses: Investigate cell-to-cell variability in VPS-33.2 expression and function using single-cell transcriptomics or proteomics approaches.

How can researchers distinguish between CHEVI and HOPS complex functions using VPS-33.2 antibodies?

To differentiate between the functions of VPS-33.2 in CHEVI versus VPS-33.1 in HOPS:

• Co-immunoprecipitation analysis: Use VPS-33.2 antibodies to pull down CHEVI components (specifically SPE-39/VIPAS39) but not HOPS-specific components .

• Comparative immunofluorescence: Perform colocalization studies with markers for:

  • CHEVI complex (VPS-33.2 + SPE-39/VIPAS39)

  • HOPS complex (VPS-33.1 + other HOPS components)

  • Membrane compartments associated with each complex

• Mutant phenotype analysis: Compare cellular phenotypes between:

  • VPS-33.2/VPS33B deficiency (CHEVI dysfunction)

  • VPS-33.1/VPS33A deficiency (HOPS dysfunction)

  • SPE-39/VIPAS39 deficiency (CHEVI dysfunction)

• Rescue experiments: Test whether overexpression of VPS-33.1 can compensate for VPS-33.2 deficiency and vice versa in specific cellular contexts.